A5058355502- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Viral-associated cancers and disorders
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Protein Degradation and Inhibitors
- CNS Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Neutropenia and Cancer Infections
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Hematological disorders and diagnostics
- Retinoids in leukemia and cellular processes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Cancer therapeutics and mechanisms
- Genetic factors in colorectal cancer
- Hemoglobinopathies and Related Disorders
- Platelet Disorders and Treatments
- CAR-T cell therapy research
- Immunodeficiency and Autoimmune Disorders
Ariel University
2018-2025
Assuta Medical Center
2016-2025
Rabin Medical Center
2010-2023
Tel Aviv University
2009-2021
Justus-Liebig-Universität Gießen
2018
Marien Hospital Düsseldorf
2016
Heinrich Heine University Düsseldorf
2016
Roche (Switzerland)
2014
Janssen (United Kingdom)
2013
Université Claude Bernard Lyon 1
2011-2013
The standard treatment for patients with multiple myeloma who are not candidates high-dose therapy is melphalan and prednisone. This phase 3 study compared the use of prednisone or without bortezomib in previously untreated were ineligible therapy.We randomly assigned 682 to receive nine 6-week cycles (at a dose 9 mg per square meter body-surface area) 60 meter) on days 1 4, either alone 1.3 1, 8, 11, 22, 25, 29, 32 during 4 29 5 9. primary end point was time disease progression.The...
Purpose Salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT) is the standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL). regimens have never been compared; their efficacy in rituximab era unknown. Patients Methods with CD20 + DLBCL first relapse or who were refractory after first-line randomly assigned to either rituximab, ifosfamide, etoposide, carboplatin (R-ICE) dexamethasone, cytarabine, cisplatin (R-DHAP). Responding...
PURPOSE Recipients of allogeneic bone marrow transplants (BMTs) who have relapsed may attain complete remissions when treated with transfusions leukocytes obtained from the original donor. We performed a retrospective study to characterize better this new treatment modality. PATIENTS AND METHODS surveyed 25 North American BMT programs regarding their use donor leukocyte infusions (DLI). Detailed forms were used gather data BMT, relapse, DLI, response complications and long-term follow-up...
The purpose of this study was to confirm overall survival (OS) and other clinical benefits with bortezomib, melphalan, prednisone (VMP) versus melphalan (MP) in the phase III VISTA (Velcade as Initial Standard Therapy Multiple Myeloma) trial after prolonged follow-up, evaluate impact subsequent therapies.Previously untreated symptomatic patients myeloma ineligible for high-dose therapy received up nine 6-week cycles VMP (n = 344) or MP 338).With a median follow-up 36.7 months, there 35%...
The standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT). impact of maintenance rituximab after ASCT not known.In total, 477 patients with CD20(+) DLBCL who were in their first relapse or refractory to initial randomly assigned one two regimens. After three cycles chemotherapy, the responding received ASCT. Then, 242 either every 2 months 1 year observation.After ASCT, 122...
This final analysis of the phase III VISTA trial (Velcade As Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and Prednisone) was conducted to determine whether overall survival (OS) benefit with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) patients myeloma who were ineligible for transplantation maintained after 5 years follow-up explore risk second primary malignancies.In all, 682 received up nine 6-week cycles VMP or MP then observed every...
This international phase III, randomized, placebo-controlled, double-blind study assessed the efficacy and safety of lenalidomide in RBC transfusion-dependent patients with International Prognostic Scoring System lower-risk non-del(5q) myelodysplastic syndromes ineligible for or refractory to erythropoiesis-stimulating agents.In total, 239 were randomly assigned (2:1) treatment (n = 160) placebo 79) once per day (on 28-day cycles). The primary end point was rate transfusion independence (TI)...
BackgroundAdding ibrutinib to standard immunochemotherapy might improve outcomes and challenge autologous stem-cell transplantation (ASCT) in younger (aged 65 years or younger) mantle cell lymphoma patients. This trial aimed investigate whether the addition of results a superior clinical outcome compared with pre-trial ASCT an ibrutinib-containing treatment without ASCT. We also investigated is adding but ASCT.MethodsThe open-label, randomised, three-arm, parallel-group, superiority TRIANGLE...
Summary Belinostat is a pan‐histone deacetylase inhibitor with antitumour and anti‐angiogenic properties. An open label, multicentre study was conducted in patients peripheral T‐cell lymphoma ( PTCL ) or cutaneous CTCL who failed ≥1 prior systemic therapy were treated belinostat (1000 mg/m 2 intravenously ×5 d of 21‐d cycle). The primary endpoint objective response rate ORR ). Patients n = 24) had received median three therapies (range 1–9) 40% stage IV disease. 29) one skin‐directed 0–4)...
The utility of [(18)F]fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in assessing response at the end induction therapy is well documented Hodgkin's and diffuse large B-cell lymphomas, but its role follicular lymphoma (FL) remains undetermined. We investigated prognostic significance PET-CT performed after first-line patients with FL treated prospective Primary Rituximab Maintenance (PRIMA) study.Results scans immunochemotherapy were recorded...
Relapsed adult acute lymphoblastic leukemia (ALL) is associated with high reinduction mortality, chemotherapy resistance, and rapid progression leading to death. Vincristine sulfate liposome injection (VSLI), sphingomyelin cholesterol nanoparticle vincristine (VCR), facilitates VCR dose-intensification densification plus enhances target tissue delivery. We evaluated high-dose VSLI monotherapy in adults Philadelphia chromosome (Ph) -negative ALL that was multiply relapsed, relapsed refractory...
Purpose To assess bortezomib plus melphalan and prednisone (VMP) (MP) in previously untreated patients with multiple myeloma (MM) renal impairment enrolled on the phase III VISTA study, to evaluate reversibility. Patients Methods received nine 6-week cycles of VMP (bortezomib 1.3 mg/m 2 , 9 60 ) or MP. serum creatinine higher than mg/dL were excluded. Results In VMP/MP arms, 6%/4%, 27%/30%, 67%/66% had baseline glomerular filtration rate (GFR) ≤ 30, 31 50, 50 mL/min, respectively. Response...